ArticleDrugs - real world outcomes2021
Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy.
Article in Drugs - real world outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Coagulation profiles and factor XIII activity in pediatric patients with severe motor and intellectual disability: a multicenter exploratory study.International journal of hematology · 2026Article
- Performance of triggers in detecting hospitalizations related to drug-induced respiratory disorders in older adults: A pilot cross-sectional study.Clinics (Sao Paulo, Brazil) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacokinetics and pharmacodynamics of drugs in elderly individuals differ from those in younger adults; thus, adverse drug events (ADEs) are common in older patients with polypharmacy because co-existing comorbidities elevate the risk of ADEs occurring. However, ADEs have not yet been characterised based on the elderly patients of Japanese origin and polypharmacy.
objectiveThe 100 most commonly reported ADEs were grouped into four classes (Class 1-Class 4) based on elderly patients with polypharmacy. PATIENTS AND
methodsIn this study, logistic regression analysis was performed using cases recorded in the Japanese Adverse Drug Event Report (JADER) database.
resultsADEs in elderly patients treated with polypharmacy-in whom the risk of electrolyte abnormalities, renal and respiratory disorders, and coagulopathy was high-were categorised as 'Class 1 [E(+), P(+)]', while ADEs in elderly patients not treated with polypharmacy-in whom the risk of delirium and fall was high-were categorised as 'Class 2 [E(+), P(-)]'. When there was no association with being elderly, ADEs associated with polypharmacy that carried a high risk of myelosuppression and infection were categorised as 'Class 3 [E(-), P(+)]', and allergic ADEs that were not affected by being elderly or polypharmacy, were categorised as 'Class 4 [E(-), P(-)]'. Class 1 events as well as Class 3 ADEs occurred more frequently in females than in males, whereas Class 3 ADEs (deep vein thrombosis and pulmonary embolism) occurred more frequently in males.
conclusionsClass 1 and Class 2 ADEs should be investigated in analyses that focus on individual drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.